A double-blind crossover study was performed on 27 patients with proved fixed coronary artery disease and stable angina pectoris. The study was designed to com• pare the relative efficacy of two combination therapies, nifedipine plus propranolol and isosorbide dinitrate plus propranolol, in terms of antianginal response and effect on exercise tolerance by evaluation of treadmill testing. The combination of nifedipine and propranolol was su• perior to the combination of isosorbide and propranolol in reducing the number of anginal attacks (p = 0.03), increasing total exercise time (p < 0.02), increasing ox• ygen consumption achieved at end of exercise (p < 0.03), increasing time to onset of pain (p = 0.003) and in• creasing oxygen consumption achieved at onset of pain (p = 0.003). Analysis of the rate-pressure products sugTherapy with combinations of different antianginal medi• cations has gained increasing favor by optimizing treatment for patients with symptomatic angina pectoris. The use of adjunctive therapy allows for selective titration of appro• priate antianginal agents in an effort to individualize treat• ment to each patient's needs, improve clinical outcome and reduce unwanted side effects. In this regard, coadministra• tion of long-acting nitrate preparations with beta-adreno• receptor blocking agents has been the most common form of combination therapy for patients with angina who either are refractory to monotherapy or are unsuitable candidates for coronary revascularization surgery (l,2).
gests that the difference in these results may be explained by the greater effect of nifedipine on afterload reduction. Although nitroglycerin consumption was reduced from baseline levels during combination nifedipine therapy (p < 0.001), there was no statistical difference between nifedipine combination therapy and isosorbide combi• nation therapy.
In conclusion, although both combination therapies were superior to propranolol therapy alone, the com• bination of nifedipine and propranolol was more effec• tive than the combination of isosorbide and propranolol in reducing the incidence of angina and improving ex• ercise performance. Side effects were experienced at a similar frequency during both combination therapies.
(J Am Coil CardioI1985; 6:1395-401) blocking agents, new choices exist regarding the selection of an adjunctive agent. Although numerous investigations have demonstrated improved antianginal effect when nifed• ipine is added to propranolol (3) (4) (5) (6) (7) (8) , little information is available comparing different combination therapies with each other. This randomized double-blind crossover study was designed to compare the relative efficacy of two dif• ferent antianginal combination therapies, propranolol plus nifedipine and propranolol plus long-acting nitrates, with each other as well as with propranolol alone.
Methods
Inclusion criteria. Informed consent was obtained from 30 patients at the time of study entry. All patients were between 35 and 75 years of age and were required to have had at least four episodes of angina per week during the month before study enrollment despite propranolol therapy.
Evidence of adequate beta-blockade, defined as the dose of propranolol providing a heart rate at rest of less than 60 beats/min or a peak heart rate of less than 125 beats/min on exercise treadmill testing, was required for study entry. The diagnosis of coronary artery disease was confirmed in all patients by either coronary arteriography (2: 70% stenosis of at least one major coronary artery), a positive exercise treadmill test (2: I mm horizontal ST segment depression 0.08 second beyond the J point) or a history of previous myocardial infarction.
Exclusion criteria. Patients were excluded from study entry if they had evidence of symptomatic congestive heart failure, arrhythmias refractory to conventional therapy, un• controlled hypertension or insulin-dependent diabetes mel• litus. Patients who had had a myocardial infarction within the month before enrollment or who had undergone aorto• coronary bypass surgery within the 6 month period before enrollment were excluded from the study.
Protocol. Of the 30 patients entered, 27 were evaluable. One patient's data were excluded because of poor drug compliance and unreliable documentation of anginal epi• sodes. A second patient experienced sudden death before study completion while receiving nifedipine-propranolol ad• junctive therapy. A third patient was withdrawn from the study during the baseline period because of insufficient fre• quency of angina when propranolol was titrated to tolerance. Of the remaining 27 patients, 23 were male and 4 female with a mean age of 61.2 years (range 45 to 74). Twelve patients had a history of previous myocardial infarction; 25 patients had a positive coronary angiogram. All patients, except one, had an exercise tolerance test diagnostic of myocardial ischemia before study entry.
Patients entered into the protocol once an adequate dose of propranolol as defined had been established. The median dose of propranolol was 120 mg/day (range 60 to 240). This dose was maintained at a constant level throughout the study. At the end of the first week, an exercise tolerance test was performed to neutralize training effect and to ensure that adequate beta-receptor blockade had been achieved. All pa• tients then entered a 2 week single-blind phase during which placebo was added to their established dose of propranolol. A second exercise test obtained at the end of this placebo• propranolol period served as the baseline stress test.
The patients were then randomized into one of the two study drug treatment groups, receiving either propranolol plus nifedipine (adjunctive nifedipine) or propranolol plus isosorbide dinitrate (adjunctive isosorbide) administered or• ally four times daily in a double-blind, double-dummy fash• ion. The two treatment phases were identical in structure and consisted of 3 weeks of safety titration to the maximally tolerated dose of study medication followed by 3 weeks of a fixed dose of study drug at the maximal dosage achieved during the safety titration period. After a repeat exercise tolerance test, performed at the end of the first 6 week period, patients were crossed over to the alternate study drug treatment regimen in which an identical protocol was used.
Dosage of study medications ( functional capacity, heart rate and blood pressure response to exercise were assessed using a modified Balke-Ware pro• tocol ( Table 2 ). The efficacy of the two adjunctive treatment regimens was analyzed during the final week of each of the fixed dose periods (that is, study weeks 9 and IS). Patients unable to tolerate adjunctive isosorbide were exercised be• fore crossover to nifedipine or termination of isosorbide therapy. Statistical analyses included an analysis of variance for crossover design.
Results
A summary of the individual data points for all patients showing frequency of anginal attacks, number of nitro• glycerin tablets consumed and total exercise duration during the three phases of the trial is presented in Table 3 .
Anginal attacks. The frequency of angina during the three phases of therapy, propranolol plus placebo (baseline phase), propranolol plus isosorbide dinitrate (adjunctive iso• sorb ide) and propranolol plus nifedipine (adjunctive nifed• ipine) is depicted in Figure I . Both adjunctive isosorbide (p < 0.001) and adjunctive nifedipine (p < 0.001) resulted Patients exercised longer and to a greater work load than at baseline with both study medications, but nifedipine was more effective than isosorbide at a highly significant level.
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• ISOSORBIDE AND PROPRANOLOL ~ NIFEDIPINE AND PROPRANOLOL icant differences, possibly because of the wide variability in nitroglycerin consumption that occurred during the ad• junctive isosorbide phase. Exercise stress testing. Exercise performance of the three different treatment groups is summarized in Figures 2 and  3 . Total exercise duration, work load achieved at peak ex• ercise, time to onset of angina and work load achieved at onset of angina were the variables selected for evaluation. Both combination therapies-adjunctive isosorbide and ad• junctive nifedipine-were superior to propranolol alone in prolonging total exercise time. However, adjunctive nifed• ipine resulted in a statistically significant increase in total exercise time when compared with adjunctive isosorbide dinitrate (p < 0.02). The work load achieved at end-exercise was significantly higher during both adjunctive treatment phases compared with propranolol alone (p = 0.001). The increase was higher during adjunctive nifedipine therapy than during adjunctive isosorbide dinitrate therapy (p < 0.03).
Of the 27 patients evaluated, 14 experienced angina dur• ing both active drug treatment arms of the study (Fig. 3) . Time to onset of angina was significantly prolonged during adjunctive nifedipine therapy compared with adjunctive iso• sorb ide (p = 0.003) or propranolol therapy (p < 0.00l).
In addition, the peak work load achieved at onset of pain was significantly higher during adjunctive nifedipine therapy as compared with either adjunctive isosorbide (p = 0.003) or propranolol (p < 0.001) therapy.
Effect on rate-pressure product. The rate-pressure product (double product) at peak exercise and at submaximal (Fig. 4) . Because of a decrease in both heart rate and systolic blood pressure, the rate-pressure product at submaximal exercise was significantly lower during ad• junctive nifedipine therapy than during adjunctive isosorbide dinitrate or propranolol therapy (Fig. 5) . However, at the onset of angina in 14 patients, and at end-exercise in all 27 patients, no statistically significant difference was observed between the rate-pressure product recorded during the pro• pranolol baseline period and that recorded during either adjunctive treatment phase (Fig. 6) . Although 27 patients experienced angina on treadmill testing when receiving propranolol alone, 13 patients had a fatigue-limited exercise test during one or both adjunctive treatment periods. Ten patients were pain-free during ad• junctive nifedipine administration and six patients during adjunctive isosorbide administration. The rate-pressure products achieved at end-exercise by these patients were not significantly different from those achieved by the 14 patients with a symptom-limited exercise test during ad• junctive therapy or from those achieved by all patients dur• ing the propranolol baseline phase.
Adverse effects. During both adjunctive treatment phases, approximately one-half of the patients reported side effects judged to be mild to moderate, although three patients re• quired premature crossover from isosorbide to nifedipine ajunctive therapy because of intolerable headache experi• enced with isosorbide. Side effects were encountered at a similar frequency during both adjunctive phases and con• sisted primarily of headache during the isosorbide adjunctive phase and lightheadedness, pedal edema and gastrointestinal upset during the adjunctive nifedipine phase. However, pa-HEART RATE (OBTAINED AT SUBMAXIMAL WORKLOAD)
BLOOD PRESSURE (OBTAINED AT SUBMAXIMAL WORKLOAD) Figure 5 . Components of the rate-pressure product (double product) at submaximal work load. At the end of stage I, there was a highly significant difference in both blood pressure and heart rate when patients were taking adjunctive nifedipine compared with adjunctive isosorbide or propranolol alone. tients whose dose of isosorbide could be titrated beyond the initial dose appeared to have fewer long-term side effects than those patients receiving adjunctive nifedipine.
Discussion
Clinical relevance. At present, three classes of phar• macologic agents provide realistic therapeutic alternatives for physicians treating patients with angina pectoris. Interest in defiI1ing optimal medical treatment for angina is rising given the recent findings of the Coronary Artery Surgery Study (CASS) demonstrating equivalent survival rates after medical and surgery therapy in certain symptomatic patients with coronary artery disease (9) . Beta-adrenergic blocking agents and long-acting nitrates either alone or in combi• nation reduce the frequency of angina and improve the qual• ity of life in many symptomatic patients. The introduction of calcium channel blockers now adds an additional ther• apeutic alternative to long-acting nitrates as combination treatment with beta-blocker medication. The present study was conceived to examine the commonly encountered clin• ical question of which agent or agents to add when patients remain symptomatic despite maximally tolerated doses of a beta-blocker.
Nifedipine effectively reduces angina when used as a single agent (10, 11) , and several studies (3) (4) (5) (6) (7) (8) 12) Therapeutic benefits. This was a randomized double• blind crossover investigation utilizing a study group that remained symptomatic despite adequate beta-blockade. Study medications were titrated individually to tolerance. A de• tailed analysis of the data obtained during chronic coad• ministration of each study medication plus propranolol was performed using patient diaries of anginal episodes and ni• troglycerin tablet counts to assess clinical efficacy. Clearly both combination therapies proved superior to propranolol alone in reducing the frequency of anginal attacks. How• ever, an additional statistically significant reduction could be demonstrated when adjunctive nifedipine therapy was compared with adjunctive isosorbide dinitrate therapy. Fur• thermore, only with adjunctive nifedipine therapy was there a significant reduction in nitroglycerin consumption com• pared with the baseline period when patients were taking propranolol alone.
A second goal of management of angina is the attempt to improve patient life-style by improving exercise perform• ance with drug therapy. Several variables of exercise per• formance were measured during this study including total exercise time, time to onset of angina, work load achieved at end of exercise and work load achieved at onset of angina. Although both adjunctive therapies improved exercise per• formance when compared with propranolol alone, the im• provement observed was significantly greater during ad• junctive nifedipine therapy than during adjunctive isosorbide dinitrate therapy. This improvement was seen in all four patient response categories and the differences were highly significant.
Mechanism of action. To reduce myocardial ischemia, any antianginal agent, whether used alone or in combina• tion, must favorably affect the balance between myocardial oxygen supply and demand. In our study, adjunctive nifed• ipine therapy was more effective than adjunctive isosorbide dinitrate therapy in reducing the rate-pressure product at submaximal exercise (Fig. 5) , a mechanism that may ac• count for the ability of the nifedipine-propranolol combi• nation to prolong exercise time. Because systolic blood pres• sure is an important determinant of left ventricular wall tension and myocardial oxygen consumption during exer• tion, it is conceivable that afterload (affected by nifedipine) is more important than preload (affected by nitrates) as a determinant of myocardial oxygen demand during exercise when diastolic filling time is substantially shortened, Fur• thermore, the reflex increase in heart rate, frequently cited as a negative aspect of either nifedipine or nitrate mono• therapy, was abolished during coadministration with propranolol.
In addition to the beneficial effect of nifedipine on the peripheral circulation, other mechanisms may explain this agent's efficacy when used adjunctively with propranolol. Numerous studies (13) have suggested that nifedipine en• hances coronary blood flow, with concomitant beneficial effects on angina threshold and maximal exercise capacity. Malacoff et al. (14) observed that nifedipine improved myo• cardial blood flow in regions of myocardium subserved by coronary artery segments with significant stenoses. In ad• dition, Engel and Lichtlen (15) noted improved coronary blood flow in poststenotic regions when nifedipine was ad• ministered during atrial pacing compared with the results obtained when propranolol and nitroglycerin were admin• istered, The recent observation that propranolol may ac• tually potentiate coronary vasoconstriction when patients are challenged with cold pressor testing (16) provides another possible explanation for the observed efficacy of nifedipine since this agent may exert a selective antivasoconstrictor effect on the coronary vasculature (7) .
Although the rate-pressure products observed at end-ex• ercise after the addition of either nifedipine or isosorbide dinitrate were not significantly different from propranolol baseline values, 13 of 27 patients discontinued exercise because of fatigue rather than angina. The fact that these patients (who were predominantly, but not exclusively, in the nifedipine group) were limited by fatigue rather than pain at comparable rate-pressure products suggests that an increase in myocardial blood flow may be a factor in im• proving exercise capacity in this particular cohort of patients.
Conclusions. This study demonstrated that adjunctive administration of nifedipine or isosorbide dinitrate with pro• pranolol is more effective than propranolol alone in reducing symptomatic angina pectoris, The combination of nifedipine and propranolol appears to be significantly more effective than the combination of isosorbide dinitrate and propranolol in reducing angina and improving exercise performance dur-ing standardized exercise tolerance tests. Side effects were encountered at a similar frequency during both combination therapies.
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